SUSMED, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3319150003
JPY
870.00
-13 (-1.47%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
GNI Group Ltd.
OncoTherapy Science, Inc.
Cyfuse Biomedical KK
MEDINET Co., Ltd.
SUSMED, Inc.
Stella Pharma Corp.
Oncolys BioPharma, Inc.
Chiome Bioscience, Inc.
StemCell Institute
Peptidream, Inc.
Carna Biosciences, Inc.
Why is SUSMED, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.04%
  • The company has been able to generate a Return on Equity (avg) of 0.04% signifying low profitability per unit of shareholders funds
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.04%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 48.72%, its profits have risen by 21.3%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is SUSMED, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
SUSMED, Inc.
48.72%
0.88
59.01%
Japan Nikkei 225
27.57%
1.07
25.74%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-7.15%
EBIT Growth (5y)
-1,268.24%
EBIT to Interest (avg)
-215.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.09
Tax Ratio
0.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.04%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.17
EV to EBIT
-18.44
EV to EBITDA
-18.89
EV to Capital Employed
-172.48
EV to Sales
11.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-6.24%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
NET SALES(HY)

Higher at JPY 389.28 MM

NET PROFIT(HY)

Higher at JPY 14.57 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 60.71%

-10What is not working for the Company
NET SALES(Q)

At JPY 44.51 MM has Fallen at -60.71%

PRE-TAX PROFIT(Q)

At JPY -151.98 MM has Fallen at -116.7%

NET PROFIT(Q)

At JPY -152.28 MM has Fallen at -116.2%

DEBT-EQUITY RATIO (HY)

Highest at 0 %

Here's what is working for SUSMED, Inc.
Inventory Turnover Ratio
Highest at 60.71%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for SUSMED, Inc.
Net Sales
At JPY 44.51 MM has Fallen at -60.71%
over average net sales of the previous four periods of JPY 113.29 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit
At JPY -151.98 MM has Fallen at -116.7%
over average net sales of the previous four periods of JPY -70.13 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit
At JPY -152.28 MM has Fallen at -116.2%
over average net sales of the previous four periods of JPY -70.44 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Debt-Equity Ratio
Highest at 0 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio